These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32999432)

  • 21. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
    Severa M; Farina C; Salvetti M; Coccia EM
    Front Immunol; 2020; 11():1459. PubMed ID: 32655578
    [No Abstract]   [Full Text] [Related]  

  • 22. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
    Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
    Pang X; Cui Y; Zhu Y
    Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
    [No Abstract]   [Full Text] [Related]  

  • 25. A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell Culture.
    Shema Mugisha C; Vuong HR; Puray-Chavez M; Bailey AL; Fox JM; Chen RE; Wessel AW; Scott JM; Harastani HH; Boon ACM; Shin H; Kutluay SB
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19: A Defining Moment for Clinical Pharmacology?
    van der Graaf PH; Giacomini KM
    Clin Pharmacol Ther; 2020 Jul; 108(1):11-15. PubMed ID: 32350861
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
    Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Perspective of Antiviral Strategies against COVID-19.
    Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
    ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactoferrin as potential preventative and adjunct treatment for COVID-19.
    Chang R; Ng TB; Sun WZ
    Int J Antimicrob Agents; 2020 Sep; 56(3):106118. PubMed ID: 32738305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19: Small-Molecule Clinical Trials Landscape.
    Ferreira LLG; Andricopulo AD
    Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
    [No Abstract]   [Full Text] [Related]  

  • 31. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.
    Madhusoodanan J
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10616-10620. PubMed ID: 32350142
    [No Abstract]   [Full Text] [Related]  

  • 32. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options.
    Asghari A; Naseri M; Safari H; Saboory E; Parsamanesh N
    DNA Cell Biol; 2020 Oct; 39(10):1741-1753. PubMed ID: 32716648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
    Kara E; Demirkan K; Unal S
    Int J Antimicrob Agents; 2020 Sep; 56(3):106123. PubMed ID: 32738307
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.
    Migaud M; Gandotra S; Chand HS; Gillespie MN; Thannickal VJ; Langley RJ
    Am J Respir Cell Mol Biol; 2020 Sep; 63(3):396-398. PubMed ID: 32574504
    [No Abstract]   [Full Text] [Related]  

  • 36. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
    Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
    Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
    Tian L; Liu W; Sun L
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
    Hage-Melim LIDS; Federico LB; de Oliveira NKS; Francisco VCC; Correia LC; de Lima HB; Gomes SQ; Barcelos MP; Francischini IAG; da Silva CHTP
    Life Sci; 2020 Sep; 256():117963. PubMed ID: 32535080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Targets in the Chemotherapy of Coronavirus Infection.
    Zhirnov OP
    Biochemistry (Mosc); 2020 May; 85(5):523-530. PubMed ID: 32571182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Okamoto M; Toyama M; Baba M
    Antiviral Res; 2020 Oct; 182():104902. PubMed ID: 32739404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.